66 Scientists are exploring a new way to treat brain cancer by using naturally produced nanoparticles called exosomes, which could revolutionise how drugs are delivered to tumours in the brain. These tiny vesicles, created by the body’s own cells, can travel across the blood–brain barrier and directly target cancer cells, offering a more precise and less harmful alternative to conventional treatments. The findings were published in the journal Cancer Cell International. Brain cancer remains one of the most difficult types of cancer to treat. Surgery, chemotherapy, and radiation often come with serious side effects and may not completely eliminate the tumour. A major challenge in treating brain tumours is the blood brain barrier, a protective layer that prevents most medications from reaching the brain. Exosomes, however, have the ability to cross this barrier, making them ideal candidates for delivering drugs directly to tumours. The research, led by a team at Tanta University in Egypt, highlights how exosomes can be loaded with anticancer agents and directed to specific tumour cells. These vesicles can be engineered to recognise and bind to malignant cells, ensuring the drug payload reaches the right target. This approach could greatly reduce damage to healthy brain tissue and improve the effectiveness of treatment. Compared to traditional drug carriers like liposomes or micelles, exosomes offer several advantages. They have lower toxicity, better compatibility with human cells, and a natural ability to navigate complex biological environments. Their small size and flexible structure allow them to move through tumour tissues more effectively, and they can be modified to carry various types of treatments, including chemotherapy drugs and gene-based therapies. However, challenges remain. Producing large quantities of exosomes that are pure and consistent is still difficult. Researchers are experimenting with ways to increase output, such as using stem cells, altering genetic pathways, or even sourcing exosomes from milk and plants. Some scientists are also exploring how environmental stress, like low oxygen or oxidative conditions, can boost exosome production. Despite these obstacles, early experiments in mice have shown promising results. Tumours shrank significantly when treated with exosome-based therapies compared to standard drug delivery methods. Trials involving milk-derived exosomes have even shown that drugs can be taken orally, making the treatment process easier for patients. The interaction between exosomes and the tumour microenvironment is also under close study. These vesicles not only carry drugs but can also influence how cancer cells grow, move, and respond to the immune system. Understanding this complex interaction may help researchers fine-tune exosome therapies to halt tumour progression or prevent relapse. Although still in the research phase, exosome-based treatment represents a major step forward in personalised medicine. If production hurdles can be overcome, these lab-grown vesicles could become a cornerstone in the fight against brain cancer, offering patients more targeted and less invasive options.